

2023 Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 1A-B

Module 1A: Pharmacogenomics, Statistics, Pediatric Malignancy

Volume 1

Articles and Learning Objectives

Module 1A: Pharmacogenomics, Statistics, Pediatric Malignancy

ACPE #: 0204-9999-23-952-H01-P

Pharmacogenomics

Article:

Chekravarty D et al. Somatic Genomic Testing in Patients with Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. *J Clin Oncol.* 2020; 40(11):1231-58.

Learning Objectives:

- Describe the provisional clinical opinion from the American Society of Clinical Oncology (ASCO) for the use of somatic genomic testing and biomarker-guided therapies in patients with metastatic or advanced cancer.
- Develop recommendations for the use of somatic genomic testing and biomarker-guided therapies in patients with metastatic or advanced cancer.
- Select appropriate patients to receive biomarker-guided therapies based on the ASCO provisional clinical opinion for somatic genomic testing.

Statistics

Articles:

Anagnostou V et al. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity. *Clin Cancer Res.* 2017; 23:4959-69.

Doki Y et al. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. *N Engl J Med.* 2022; 386:449-62.

Learning Objectives:

- Describe various endpoints used in an immuno-oncology trial.
- Select appropriate patients to receive nivolumab in combination for a patient with advanced esophageal squamous-cell carcinoma based on the results of an immuno-oncology trial.
- Interpret an immuno-oncology trial using nivolumab in combination for a patient with advanced esophageal squamous-cell carcinoma.

Pediatric Malignancy

Article:

Brown PA, Ji L, Xu X et al. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. *JAMA*. 2021; 325(9):833–842.

Learning Objectives:

- Describe the study of blinatumomab for relapsed B-cell acute lymphoblastic leukemia in children, adolescents and young adults with first relapse.
- Select appropriate patients to receive blinatumomab based on the results of the study by Brown, et al.
- Develop recommendations for the management of first relapse of B-cell acute lymphoblastic leukemia in children, adolescents and young adults.

2023 Oncology Pharmacy Specialty Home Study Syllabus for Recertification: Module 1A-B

Module 1B: Hepatocellular Carcinoma, Urothelial Carcinoma, Pharmacy Practice Management, Lymphoma

Volume 1

Articles and Learning Objectives

Module 1B: Hepatocellular Carcinoma, Urothelial Carcinoma, Pharmacy Practice Management, Lymphoma

ACPE #: 0204-9999-23-953-H01-P

Hepatocellular Carcinoma

Article:

Kelley et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2022; 23: 995–1008.

Learning Objectives:

- Describe the COSMIC-312 study of cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma.
- Develop recommendations for the use of cabozantinib plus atezolizumab in patients with advanced hepatocellular carcinoma.
- Select appropriate patients to receive cabozantinib plus atezolizumab based on the results of the COSMIC-312 study.

Urothelial Carcinoma

Article:

Barjorin DF et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. *N Engl J Med.* 2021; 384:2102-14.

Learning Objectives:

- Describe the study of adjuvant nivolumab for muscle-invasive bladder cancer in newly diagnosed patients following surgical resection.
- Develop recommendations for the use of adjuvant nivolumab in patients with muscle-invasive bladder cancer.
- Select appropriate patients to receive adjuvant nivolumab based on the results of CheckMate 274 by Bajorin et al.

Pharmacy Practice Management

Article:

Nahleh Z, Lyman GH, Schilsky RL et al. Use of biosimilar medications in oncology. *J Oncol Pract.* 2022; 18:177-86.

Learning Objectives:

- Describe the overview of biosimilar agents for the therapeutic use in cancer from the American Society of Clinical Oncology (ASCO).
- Develop recommendations for the use of biosimilars for therapeutic use in oncology patients and inclusion in future ASCO clinical guidelines.
- Select appropriate patients to receive biosimilar medications based on the ASCO summary of the current agents available for the therapeutic treatment of cancer.

Lymphoma

Article:

Kamdar M, Solomon S, Arnason J et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. *Lancet.* 2022; 399(10343):2294-2308.

Learning Objectives:

- Describe the TRANSFORM study of lisocabtagene maraleucel versus the standard of care for the second-line treatment of relapsed or refractory large B-cell lymphoma.
- Develop recommendations for the use of lisocabtagene maraleucel for the second-line treatment of diffuse large B-cell lymphoma.